CASI Pharmaceuticals, Inc. - CASI Future Profit

Corporate emblem and logo of CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals minimizes risks by licensing advanced oncology and hematology therapies for the Chinese region. The forward yield metric allows for tracking profit dynamics, where the parameter has stabilized at . The company is expanding its presence in Asian biomedicine through partnerships with Western centers. Meanwhile, the business successfully maneuvers between US and PRC regulators, maintaining resilience amid geopolitical pressure.

CASI: CASI Pharmaceuticals, Inc Expected Profit 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for CASI Pharmaceuticals, Inc (CASI)

- price and consensus price forecast:
Price Chart casipharmaceuticals.com|CASI - Fair Value Consensus
- issuer market value details:
Market Valuation CASI|CASI - Value Adjusted for Debt and Cash
- book capitalization information:
Book Value per Share CASI Pharmaceuticals|CASI - Company Book Value|Market Value to Book Value Ratio casipharmaceuticals.com|CASI - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity CASI Pharmaceuticals|CASI - Long-Term Liabilities to Capital|Short-Term Debt to Equity CASI Pharmaceuticals Inc.|CASI - Company Cumulative Debt|Debts to Book Capitalization CASI Pharmaceuticals, Inc|CASI - Company Long-Term Indebtedness|Company Short-Term Debts CASI Pharmaceuticals|Quick Ratio casipharmaceuticals.com
- earnings and valuation multiples information:
CASI - Net Profit|Expected Profit CASI Pharmaceuticals|CASI - Business Payback Period|Forward P/E Multiple CASI Pharmaceuticals, Inc.|CASI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio CASI|CASI - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months CASI Pharmaceuticals|CASI - Earnings per one share for the last 12 months|Quarterly EPS earnings growth casipharmaceuticals.com|CASI - Earnings per share increase in current year|Earnings growth forecast for next year CASI Pharmaceuticals
- company sales and revenue statistics:
CASI - Revenue and Sales Volume|Company Projected Revenue casipharmaceuticals.com|CASI - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio CASI|CASI - Revenue Growth YoY (Last 12 Months)
Fundamental company analysis:CASI Pharmaceuticals, Inc, CASI
Core merchandise of CASI Pharmaceuticals Inc.

For CASI Pharmaceuticals, which is introducing oncology drugs to the Chinese market, the extrapolation of future profits serves as an indicator of market confidence in the portfolio's commercial success. This metric reflects the mathematical difference between expected revenues and total projected costs. This calculation allows for the verification of official management statements through the lens of analyst consensus. The company's licensing model minimizes R&D risks, making profit dynamics more predictable. It is critical for investors to monitor discrepancies between this forecast and actual financial reports.

Competing companies

Expected Profit TG Therapeutics|ACLX: Expected Net Income|Future Profit IRON (Disc Medicine Corp)|SNDX (Syndax) - Expected Net Income|Projected Future Earnings KURA (Kura Oncology, Inc.)|adctherapeutics.com - Expected Profit|FHTX - Expected Profit|Expected Net Profit Vor Biopharma, Inc.|nkartatx.com (NKTX) - Expected Profit|Expected Net Profit Coeptis (COEP)|Expected Profit Actinium Pharma|Expected Net Profit Estrella Immunopharma ESLA|Projected Future Earnings MRKR|IN8bio - Net Profit Forecast|Projected Future Earnings ERNA (Eterna Therapeutics Inc.)|Projected Net Profit GT Biopharma, Inc.|APTO - Expected Profit|Company Profit Forecast biopathholdings.com BPTH|MEIP: Projected Future Earnings|Net Profit Forecast VINC